Skip to main content
Erschienen in: Journal of Neurology 1/2018

15.11.2017 | Original Communication

A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning

verfasst von: Noelle E. Carlozzi, E. A. Hahn, S. A. Frank, J. S. Perlmutter, N. D. Downing, M. K. McCormack, S. Barton, M. A. Nance, S. G. Schilling, HDQLIFE Site Investigators and Coordinators

Erschienen in: Journal of Neurology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Huntington disease is a fatal inherited neurodegenerative disease. Because the end result of Huntington disease is death due to Huntington disease-related causes, there is a need for better understanding and caring for individuals at their end of life.

Aim

The purpose of this study was to develop a new measure to evaluate end of life planning.

Design

We conducted qualitative focus groups, solicited expert input, and completed a literature review to develop a 16-item measure to evaluate important aspects of end of life planning for Huntington disease. Item response theory and differential item functioning analyses were utilized to examine the psychometric properties of items; exploratory factor analysis was used to establish meaningful subscales.

Participants

Participants included 508 individuals with pre-manifest or manifest Huntington disease.

Results

Item response theory supported the retention of all 16 items on the huntington disease quality of life (“HDQLIFE”) end of life planning measure. Exploratory factor analysis supported a four-factor structure: legal planning, financial planning, preferences for hospice care, and preferences for conditions (locations, surroundings, etc.) at the time of death. Although a handful of items exhibited some evidence of differential item functioning, these items were retained due to their relevant clinical content. The final 16-item scale includes an overall total score and four subscale scores that reflect the different end of life planning constructs.

Conclusions

The 16-item HDQLIFE end of life planning measure demonstrates adequate psychometric properties; it may be a useful tool for clinicians to clarify patients’ preferences about end of life care.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Nance MA, Sanders G (1996) Characteristics of individuals with Huntington disease in long-term care. Mov Disord 11(5):542–548CrossRefPubMed Nance MA, Sanders G (1996) Characteristics of individuals with Huntington disease in long-term care. Mov Disord 11(5):542–548CrossRefPubMed
2.
Zurück zum Zitat Kirwin JL, Edwards RA (2013) Helping patients articulate end-of-life wishes: a target for interprofessional participation. Ann Palliat Med 2(2):95–97PubMed Kirwin JL, Edwards RA (2013) Helping patients articulate end-of-life wishes: a target for interprofessional participation. Ann Palliat Med 2(2):95–97PubMed
3.
Zurück zum Zitat Booij SJ et al (2014) Thinking about the end of life: a common issue for patients with Huntington’s disease. J Neurol 261(11):2184–2191CrossRefPubMed Booij SJ et al (2014) Thinking about the end of life: a common issue for patients with Huntington’s disease. J Neurol 261(11):2184–2191CrossRefPubMed
4.
Zurück zum Zitat Booij SJ et al (2013) A plea for end-of-life discussions with patients suffering from Huntington’s disease: the role of the physician. J Med Ethics 39(10):621–624CrossRefPubMed Booij SJ et al (2013) A plea for end-of-life discussions with patients suffering from Huntington’s disease: the role of the physician. J Med Ethics 39(10):621–624CrossRefPubMed
5.
Zurück zum Zitat Booij SJ et al (2014) Perhaps the subject of the questionnaire was too sensitive: Do we expect too much too soon? Wishes for the end of life in Huntington’s Disease—the perspective of European physicians. J Huntingtons Dis 3(3):229–232PubMed Booij SJ et al (2014) Perhaps the subject of the questionnaire was too sensitive: Do we expect too much too soon? Wishes for the end of life in Huntington’s Disease—the perspective of European physicians. J Huntingtons Dis 3(3):229–232PubMed
7.
Zurück zum Zitat Dellefield ME, Ferrini R (2011) Promoting excellence in end-of-life care: lessons learned from a cohort of nursing home residents with advanced Huntington disease. J Neurosci Nurs 43(4):186–192CrossRefPubMed Dellefield ME, Ferrini R (2011) Promoting excellence in end-of-life care: lessons learned from a cohort of nursing home residents with advanced Huntington disease. J Neurosci Nurs 43(4):186–192CrossRefPubMed
8.
Zurück zum Zitat Dubinsky R et al (2004) Lifting the veil of Huntington’s disease: Recommendations to the field from the Huntington’s disease Peer Workgroup. Roberrt Wood Johnson Foundation, Princeton Dubinsky R et al (2004) Lifting the veil of Huntington’s disease: Recommendations to the field from the Huntington’s disease Peer Workgroup. Roberrt Wood Johnson Foundation, Princeton
9.
Zurück zum Zitat Klager J et al (2008) Huntington’s disease: a caring approach to the end of life. Care Manag J 9(2):75–81CrossRefPubMed Klager J et al (2008) Huntington’s disease: a caring approach to the end of life. Care Manag J 9(2):75–81CrossRefPubMed
10.
Zurück zum Zitat Mullahy CM, Jensen DK (2005) End-of-life care: a special calling for case managers. Case Manag 16(1):40–42 Mullahy CM, Jensen DK (2005) End-of-life care: a special calling for case managers. Case Manag 16(1):40–42
11.
12.
Zurück zum Zitat Carlozzi NE, Tulsky DS (2012) Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. J Health Psychol Carlozzi NE, Tulsky DS (2012) Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. J Health Psychol
14.
Zurück zum Zitat Booij SJ et al (2013) Euthanasia and physician-assisted suicide in Huntington’s disease in The Netherlands. Int Psychogeriatr 25(2):339–340CrossRefPubMed Booij SJ et al (2013) Euthanasia and physician-assisted suicide in Huntington’s disease in The Netherlands. Int Psychogeriatr 25(2):339–340CrossRefPubMed
15.
Zurück zum Zitat Perkins HS (2007) Controlling death: the false promise of advance directives. Ann Intern Med 147(1):51–57CrossRefPubMed Perkins HS (2007) Controlling death: the false promise of advance directives. Ann Intern Med 147(1):51–57CrossRefPubMed
16.
17.
Zurück zum Zitat Voogt E et al (2005) Attitudes of patients with incurable cancer toward medical treatment in the last phase of life. J Clin Oncol 23(9):2012–2019CrossRefPubMed Voogt E et al (2005) Attitudes of patients with incurable cancer toward medical treatment in the last phase of life. J Clin Oncol 23(9):2012–2019CrossRefPubMed
18.
Zurück zum Zitat Lyon ME et al (2014) A longitudinal, randomized, controlled trial of advance care planning for teens with cancer: anxiety, depression, quality of life, advance directives, spirituality. J Adolesc Health 54(6):710–717CrossRefPubMed Lyon ME et al (2014) A longitudinal, randomized, controlled trial of advance care planning for teens with cancer: anxiety, depression, quality of life, advance directives, spirituality. J Adolesc Health 54(6):710–717CrossRefPubMed
19.
Zurück zum Zitat Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A (2014) The effects of advance care planning on end-of-life care: a systematic review. Palliat Med 28(8):1000–1025CrossRefPubMed Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A (2014) The effects of advance care planning on end-of-life care: a systematic review. Palliat Med 28(8):1000–1025CrossRefPubMed
20.
Zurück zum Zitat Paulsen JS et al (2006) Preparing for preventive clinical trials: the predict-HD study. Arch Neurol 63(6):883–890CrossRefPubMed Paulsen JS et al (2006) Preparing for preventive clinical trials: the predict-HD study. Arch Neurol 63(6):883–890CrossRefPubMed
21.
Zurück zum Zitat Paulsen JS et al (2008) Detection of Huntington’s disease decades before diagnosis: the predict-HD study. J Neurol Neurosurg Psychiatry 79(8):874–880CrossRefPubMed Paulsen JS et al (2008) Detection of Huntington’s disease decades before diagnosis: the predict-HD study. J Neurol Neurosurg Psychiatry 79(8):874–880CrossRefPubMed
22.
Zurück zum Zitat Paulsen JS et al (2014) Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78CrossRefPubMedPubMedCentral Paulsen JS et al (2014) Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Hanauer DA et al (2015) Supporting information retrieval from electronic health records: a report of University of Michigan’s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). J Biomed Inform 55:290–300CrossRefPubMedPubMedCentral Hanauer DA et al (2015) Supporting information retrieval from electronic health records: a report of University of Michigan’s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). J Biomed Inform 55:290–300CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Carlozzi NE et al (2016) HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res 25(10):2441–2455CrossRefPubMed Carlozzi NE et al (2016) HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Qual Life Res 25(10):2441–2455CrossRefPubMed
25.
Zurück zum Zitat Carlozzi NE, Tulsky DS (2013) Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. J Health Psychol 18(2):212–225CrossRefPubMed Carlozzi NE, Tulsky DS (2013) Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. J Health Psychol 18(2):212–225CrossRefPubMed
26.
Zurück zum Zitat MetaMetrics (1995) The LEXILE framework for reading. MetaMetrics Inc, Durham MetaMetrics (1995) The LEXILE framework for reading. MetaMetrics Inc, Durham
27.
Zurück zum Zitat Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 11(2):136–142CrossRef Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 11(2):136–142CrossRef
28.
Zurück zum Zitat Shoulson I, Fahn S (1979) Huntington disease—clinical care and evaluation. Neurology 29(1):1–3CrossRefPubMed Shoulson I, Fahn S (1979) Huntington disease—clinical care and evaluation. Neurology 29(1):1–3CrossRefPubMed
29.
Zurück zum Zitat Marder K et al (2000) Rate of functional decline in Huntington’s disease. Huntington Study Group. Neurology 54(2):452–458CrossRefPubMed Marder K et al (2000) Rate of functional decline in Huntington’s disease. Huntington Study Group. Neurology 54(2):452–458CrossRefPubMed
30.
Zurück zum Zitat Samejima F, van der Liden WJ, Hambleton R (1996) The graded response model. In: van der Liden WJ (ed) Handbook of modern item response theory. Springer, NY, pp 85–100 Samejima F, van der Liden WJ, Hambleton R (1996) The graded response model. In: van der Liden WJ (ed) Handbook of modern item response theory. Springer, NY, pp 85–100
31.
Zurück zum Zitat Cai L, Thissen D, du Toit SHC (2011) IRTPRO for Windows [Computer software]. Scientific Software International, Lincolnwood Cai L, Thissen D, du Toit SHC (2011) IRTPRO for Windows [Computer software]. Scientific Software International, Lincolnwood
32.
Zurück zum Zitat van der Linden WJ, Hambleton RK (1997) Handbook of modern item response theory. Springer, New YorkCrossRef van der Linden WJ, Hambleton RK (1997) Handbook of modern item response theory. Springer, New YorkCrossRef
33.
Zurück zum Zitat Crane PK et al (2006) Differential item functioning analysis with ordinal logistic regression techniques. DIFdetect and difwithpar. Med Care 44(11 Suppl 3):S115–S123CrossRefPubMed Crane PK et al (2006) Differential item functioning analysis with ordinal logistic regression techniques. DIFdetect and difwithpar. Med Care 44(11 Suppl 3):S115–S123CrossRefPubMed
34.
Zurück zum Zitat Kline RB (2005) Principles and practice of structural equation modeling, 2nd edn. Guilford Press, New York Kline RB (2005) Principles and practice of structural equation modeling, 2nd edn. Guilford Press, New York
35.
Zurück zum Zitat Bentler PM (1990) Comparative fit indexes in structural models. Psychol Bull 107(2):238–246CrossRefPubMed Bentler PM (1990) Comparative fit indexes in structural models. Psychol Bull 107(2):238–246CrossRefPubMed
36.
Zurück zum Zitat Hu LT, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model Multidiscip J 6(1):1–55CrossRef Hu LT, Bentler PM (1999) Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model Multidiscip J 6(1):1–55CrossRef
37.
Zurück zum Zitat Hatcher L (1994) A step-by-step approach to using SAS for factor analysis and structural equation modeling. SAS Institute Inc, Cary Hatcher L (1994) A step-by-step approach to using SAS for factor analysis and structural equation modeling. SAS Institute Inc, Cary
38.
Zurück zum Zitat McDonald RP (1999) Test theory: a unified treatment. Lawrence Erlbaum Associates Inc, Mahwah McDonald RP (1999) Test theory: a unified treatment. Lawrence Erlbaum Associates Inc, Mahwah
39.
Zurück zum Zitat Reise SP, Morizot J, Hays RD (2007) The role of the bifactor model in resolving dimensionality issues in health outcomes measures. Qual Life Res 16(Suppl 1):19–31CrossRefPubMed Reise SP, Morizot J, Hays RD (2007) The role of the bifactor model in resolving dimensionality issues in health outcomes measures. Qual Life Res 16(Suppl 1):19–31CrossRefPubMed
40.
Zurück zum Zitat Cook KF, Kallen MA, Amtmann D (2009) Having a fit: impact of number of items and distribution of data on traditional criteria for assessing IRT’s unidimensionality assumption. Qual Life Res 18(4):447–460CrossRefPubMedPubMedCentral Cook KF, Kallen MA, Amtmann D (2009) Having a fit: impact of number of items and distribution of data on traditional criteria for assessing IRT’s unidimensionality assumption. Qual Life Res 18(4):447–460CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Muthén LK, Muthén BO (2011) Mplus User’s Guide. Muthén & Muthén, Los Angeles Muthén LK, Muthén BO (2011) Mplus User’s Guide. Muthén & Muthén, Los Angeles
42.
Zurück zum Zitat Carlozzi NE et al (2016) HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, Speech Difficulties, and Swallowing Difficulties. Qual Life Res 25(10):2417–2424CrossRefPubMedPubMedCentral Carlozzi NE et al (2016) HDQLIFE: the development of two new computer adaptive tests for use in Huntington disease, Speech Difficulties, and Swallowing Difficulties. Qual Life Res 25(10):2417–2424CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Carlozzi NE et al (2016) The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea. Qual Life Res 25(10):2429–2439CrossRefPubMedPubMedCentral Carlozzi NE et al (2016) The development of a new computer adaptive test to evaluate chorea in Huntington disease: HDQLIFE Chorea. Qual Life Res 25(10):2429–2439CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Carlozzi NE et al (2016) New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). Qual Life Res 25(10):2403–2415CrossRefPubMedPubMedCentral Carlozzi NE et al (2016) New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system). Qual Life Res 25(10):2403–2415CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Academic Press, New York Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Academic Press, New York
46.
Zurück zum Zitat DeVellis R (2017) Scale development: theory and applications. In: Bickman L, Rog DJ (eds) Applied social research methods series, 4th edn. Sage, Los Angeles DeVellis R (2017) Scale development: theory and applications. In: Bickman L, Rog DJ (eds) Applied social research methods series, 4th edn. Sage, Los Angeles
47.
Zurück zum Zitat Tibben A (2007) Predictive testing for Huntington’s disease. Brain Res Bull 72(2–3):165–171CrossRefPubMed Tibben A (2007) Predictive testing for Huntington’s disease. Brain Res Bull 72(2–3):165–171CrossRefPubMed
48.
Zurück zum Zitat Zhang Y et al (2011) Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet Part B Neuropsychiatr Genet 156B(7):751–763CrossRef Zhang Y et al (2011) Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet Part B Neuropsychiatr Genet 156B(7):751–763CrossRef
Metadaten
Titel
A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning
verfasst von
Noelle E. Carlozzi
E. A. Hahn
S. A. Frank
J. S. Perlmutter
N. D. Downing
M. K. McCormack
S. Barton
M. A. Nance
S. G. Schilling
HDQLIFE Site Investigators and Coordinators
Publikationsdatum
15.11.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 1/2018
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-017-8677-7

Weitere Artikel der Ausgabe 1/2018

Journal of Neurology 1/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.